Which PTSD Measures Are Commonly Used in EMDR Studies?
Researchers studying Eye Movement Desensitization and Reprocessing (EMDR) therapy use standardized assessment tools to measure changes in Post-Traumatic Stress Disorder (PTSD) symptoms.
These tools help researchers determine whether symptoms improve during treatment, how much they change, and whether improvements continue afterward.
Some assessments involve structured interviews conducted by trained clinicians. Others use questionnaires completed by participants themselves. Both approaches provide useful information, although they measure symptoms in different ways.
Several established instruments appear in EMDR research, including the Clinician-Administered PTSD Scale (CAPS), the PTSD Checklist (PCL), the Impact of Event Scale–Revised (IES-R), and the PTSD Symptom Scale (PSS). Other tools, including the International Trauma Questionnaire (ITQ), help researchers examine particular aspects of trauma-related symptoms.
Understanding these measures makes it easier to interpret EMDR studies and recognize the difference between symptom reduction, meaningful improvement, and no longer meeting the criteria for a PTSD diagnosis.
Why Do EMDR Studies Use Standardized PTSD Measures?
PTSD can involve intrusive memories, nightmares, avoidance, changes in thoughts and mood, and heightened reactions to reminders of traumatic experiences.
These symptoms vary between individuals. One person may experience fewer nightmares after treatment but continue avoiding certain situations. Another may report fewer intrusive memories and improvements in everyday functioning.
Standardized measures provide researchers with consistent ways to record these experiences.
In EMDR studies, researchers commonly assess participants before treatment and again afterward. Some studies include assessments during treatment or at follow-up appointments several months later.
These measurements help answer important questions:
Did participants report fewer PTSD symptoms after EMDR?
How substantial were the changes?
Did improvements differ from those observed with another treatment or comparison condition?
Did participants continue to meet the diagnostic criteria for PTSD?
Were improvements maintained after treatment ended?
Different assessment tools help answer different questions. A questionnaire may show how participants describe their symptoms, while a structured clinical interview can provide a more detailed assessment of diagnostic status.
The choice of measure is therefore an important part of how an EMDR study is designed and interpreted.
1. Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is one of the most established instruments used to assess PTSD in clinical research.
It is based on the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), a reference used to classify mental health conditions.
CAPS-5 is a structured interview administered by a trained assessor. It examines the 20 PTSD symptoms identified in DSM-5, including intrusive memories, avoidance, changes in thoughts and mood, and increased arousal or reactivity.
For each symptom, the assessor considers its frequency and intensity. The interview also examines how symptoms affect everyday functioning.
Why researchers use CAPS-5
CAPS-5 allows researchers to assess both PTSD symptom severity and whether participants meet diagnostic criteria.
This distinction matters because improvement in symptoms does not always mean that someone no longer qualifies for a PTSD diagnosis.
The U.S. Department of Veterans Affairs National Center for PTSD describes CAPS-5 as a reference standard for PTSD assessment.
Its structured format helps researchers apply consistent assessment procedures across participants.
An example from EMDR research
A 2024 randomized clinical trial by Matthijssen and colleagues compared EMDR, Visual Schema Displacement Therapy, and a waiting-list condition in adults with PTSD.
The researchers used CAPS-5 to assess PTSD symptoms and diagnostic status before treatment, afterward, and at follow-up.
Both active treatments were associated with greater PTSD symptom reduction than the waiting-list condition. The study also reported the proportions of participants who no longer met PTSD diagnostic criteria.
Because the trial was relatively small, its findings require interpretation within that limitation.
The study demonstrates how CAPS-5 can provide information about both symptom changes and diagnostic outcomes.
Further details about the instrument are available from the National Center for PTSD's CAPS-5 assessment guide.
2. PTSD Checklist for DSM-5 (PCL-5)
The PTSD Checklist for DSM-5 (PCL-5) is a widely used self-report questionnaire.
Unlike CAPS-5, it does not require a clinician to conduct an interview. Participants answer questions about their own experiences.
The questionnaire contains 20 items corresponding to the PTSD symptoms described in DSM-5.
Each item is rated from 0 to 4, producing a total score between 0 and 80. Higher scores indicate greater reported symptom severity.
The standard questionnaire asks about symptoms during the past month, although research may use a shorter assessment period when monitoring changes more frequently.
Why researchers use PCL-5
PCL-5 is practical for repeated assessments because it is relatively brief.
Researchers can use it before EMDR, during treatment, afterward, and at follow-up.
In the 2024 trial comparing EMDR with Visual Schema Displacement Therapy, researchers administered PCL-5 alongside CAPS-5.
This provided two perspectives: participants' own reports of their symptoms and structured clinician-rated assessments.
A reduction in PCL-5 scores indicates that participants are reporting fewer or less troublesome PTSD symptoms.
However, PCL-5 is primarily a symptom questionnaire. Although it can support screening and provisional diagnostic assessment, a lower score alone does not establish that someone no longer meets PTSD diagnostic criteria.
The National Center for PTSD's PCL-5 guidance explains its scoring and interpretation.
3. Impact of Event Scale–Revised (IES-R)
The Impact of Event Scale–Revised (IES-R) is a self-report questionnaire used to assess distress associated with a particular stressful or traumatic event.
It contains 22 items covering three main areas:
Intrusion: Unwanted memories, dreams, or thoughts connected with the experience.
Avoidance: Efforts to avoid reminders, thoughts, or feelings associated with the event.
Hyperarousal: Reactions such as increased alertness, irritability, or difficulty relaxing.
Participants rate how distressing these experiences have been during the previous seven days.
How IES-R has been used in EMDR studies
A 2015 pilot randomized controlled trial by Acarturk and colleagues examined EMDR among Syrian refugees experiencing post-traumatic stress symptoms.
The researchers assigned 29 adults to either EMDR or a waiting-list condition.
IES-R was a primary outcome measure used to compare trauma-related symptoms after treatment and at a four-week follow-up.
The EMDR group showed greater reductions in trauma-related distress than the waiting-list group at the post-treatment assessment.
The study was small, so its findings did not establish how well the results would generalize to larger populations.
Nevertheless, it provides a clear example of how researchers use IES-R to measure changes associated with EMDR.
What IES-R does not measure
IES-R was developed around an earlier understanding of PTSD symptoms and does not cover every aspect of the current DSM-5 criteria.
It is therefore best understood as a measure of event-related distress rather than a complete diagnostic assessment.
A lower IES-R score can indicate improvement without independently establishing that a person no longer meets PTSD diagnostic criteria.
4. PTSD Symptom Scale (PSS)
The PTSD Symptom Scale (PSS) refers to a family of instruments designed to assess PTSD symptoms.
Different versions have been developed, including self-report questionnaires and clinician-administered interviews.
Two established versions are the PTSD Symptom Scale–Self-Report (PSS-SR) and the PTSD Symptom Scale–Interview (PSS-I).
The original PSS-SR contains 17 symptom items based on earlier diagnostic criteria. Its total score ranges from 0 to 51, with higher scores indicating greater symptom severity.
Other versions differ in administration, content, or scoring.
How PSS has been used in EMDR research
A randomized clinical trial by Oprel and colleagues examined treatment approaches for PTSD associated with childhood abuse.
The study compared immediate EMDR with an approach that began with a preparatory treatment phase before EMDR.
Researchers used PSS-SR as their primary measure of self-reported PTSD symptom severity.
They administered it before treatment, after eight sessions, and at treatment completion.
The study also used CAPS-5 to assess PTSD diagnosis and symptom severity at additional assessment points.
This illustrates how researchers can combine a self-report symptom scale with a clinician-administered assessment.
Why the exact PSS version matters
Different versions of PSS are not automatically interchangeable.
They may reflect different diagnostic criteria, use different scoring procedures, or collect information through different methods.
When comparing EMDR studies, identifying the exact version helps readers understand what was measured.
It also prevents misleading comparisons between studies that use similarly named instruments but different assessment methods.
5. International Trauma Questionnaire (ITQ)
The International Trauma Questionnaire (ITQ) is a self-report instrument developed to assess PTSD and Complex Post-Traumatic Stress Disorder (CPTSD).
It follows the World Health Organization's International Classification of Diseases, 11th Revision (ICD-11).
ICD-11 recognizes PTSD and Complex PTSD as distinct diagnoses.
The ITQ assesses core PTSD symptoms, including re-experiencing, avoidance, and a continuing sense of threat.
It also assesses additional difficulties associated with Complex PTSD, including emotional regulation, negative self-concept, and relationships.
Why ITQ is relevant to trauma research
The ITQ helps researchers examine symptoms that may not be fully captured by instruments designed around DSM-5 PTSD criteria.
Its development was described in a 2018 study by Cloitre and colleagues, which evaluated the questionnaire's structure and validity.
The instrument is particularly relevant when researchers want to distinguish PTSD symptoms from the additional difficulties associated with Complex PTSD.
However, the ITQ should not be described as one of the most frequently used measures in EMDR clinical trials without research establishing that frequency.
It is included here because it is an important contemporary trauma assessment tool, not because it has the same documented history of use in EMDR trials as CAPS or the PTSD Checklist.
The National Center for PTSD's ITQ resource explains its content and interpretation.
6. Other PTSD Measures Used in EMDR Research
Not every EMDR study uses the same assessment tools.
Researchers select measures based on their research questions, the population being studied, and the diagnostic standards available when the study was conducted.
Other instruments appearing in trauma research and EMDR studies include the Davidson Trauma Scale, Harvard Trauma Questionnaire, and assessments developed for children and adolescents.
For example, a 2016 randomized controlled trial involving Syrian refugees used the Harvard Trauma Questionnaire and IES-R as its main outcome measures.
This illustrates how researchers sometimes combine different questionnaires to evaluate trauma-related symptoms.
Studies involving younger participants may use age-appropriate instruments, including the Clinician-Administered PTSD Scale for DSM-5—Child/Adolescent Version (CAPS-CA-5).
Researchers may also assess depression, anxiety, sleep, quality of life, and daily functioning.
These additional outcomes help show whether changes extend beyond PTSD symptom severity.
How Do Researchers Interpret Changes in PTSD Scores?
A lower PTSD score generally indicates reduced measured symptoms. However, researchers distinguish several kinds of improvement.
Average symptom reduction
A study may compare average symptom scores before and after treatment.
For example, imagine a group with an average PCL-5 score of 52 before EMDR and 30 afterward.
That would represent a 22-point reduction in the group's average reported symptom severity.
This is a hypothetical illustration, not a finding from a particular study.
It shows that symptoms decreased on average, but it does not reveal how much each individual improved.
It also does not, by itself, establish that EMDR caused the change.
Clinically meaningful improvement
Researchers may examine whether score changes are large enough to suggest meaningful improvement beyond ordinary measurement variation.
For PCL-5, a reduction of approximately 10 points has been suggested as an indicator of treatment response.
However, this is not a universal threshold.
A 2022 study by Marx and colleagues examined reliable and clinically significant changes in CAPS-5 and PCL-5 scores among military veterans.
The researchers found that thresholds for reliable change differed between samples.
This demonstrates why interpretation depends on the assessment instrument, population, and research methods.
No longer meeting PTSD diagnostic criteria
Some studies report how many participants no longer meet diagnostic criteria for PTSD after treatment.
This is different from reporting a reduction in average symptom scores.
A person may experience meaningful improvement while continuing to meet diagnostic criteria. Another may no longer meet the criteria but still experience some symptoms.
Structured clinical interviews can help researchers evaluate this distinction.
Follow-up outcomes
Researchers may repeat assessments weeks or months after treatment to examine whether improvements continue.
Follow-up findings provide information that immediate post-treatment scores cannot.
For more context, see Does EMDR Work Long Term? What Follow-Up Studies Show.
Can Results From Different PTSD Measures Be Compared?
Yes, but comparisons require care.
A 10-point reduction on PCL-5 does not mean the same thing as a 10-point reduction on IES-R.
The instruments contain different questions, use different scoring systems, and may reflect different diagnostic frameworks.
Researchers conducting systematic reviews and meta-analyses often use standardized effect sizes to compare outcomes across studies.
These statistical methods allow researchers to examine broader patterns without assuming that different questionnaires produce interchangeable scores.
Study design also matters.
A randomized controlled trial comparing EMDR with another treatment can answer different questions from a study that measures symptoms only before and after EMDR.
Even when researchers use the same questionnaire, differences in participants, treatment schedules, and follow-up periods can affect comparisons.
The article What Do Meta-Analyses Say About EMDR? explains how researchers combine evidence from multiple studies.
Why Do Some Studies Use Self-Report Measures Instead of Clinical Interviews?
Self-report questionnaires are generally easier to administer repeatedly and can be practical for larger studies.
They capture participants' own experiences, which are an important part of understanding treatment outcomes.
Clinician-administered interviews provide a more detailed assessment of symptoms and diagnostic criteria, but require trained assessors and additional time.
Neither approach makes the other unnecessary.
Some studies combine both methods to obtain complementary information.
This distinction is also important when evaluating online or self-guided treatment research. Participant-reported improvement can provide useful evidence about experiences and perceived symptom changes, while standardized clinical assessments can answer additional questions about symptom severity and diagnostic status.
The strength of a study's conclusions depends on how its measures fit the research design, not simply on whether a questionnaire or interview was used.
Frequently Asked Questions
1. What is the most widely recognized PTSD assessment used in clinical research?
The Clinician-Administered PTSD Scale (CAPS), including CAPS-5, is widely recognized as a reference standard for PTSD assessment. It uses a structured clinical interview to evaluate symptoms and diagnostic criteria.
2. What is the difference between CAPS-5 and PCL-5?
CAPS-5 is administered by a trained assessor, while PCL-5 is completed by the participant. Both measure PTSD symptoms, but CAPS-5 also supports a detailed clinical evaluation of diagnostic status.
3. Does a lower PTSD score mean EMDR has worked?
A lower score indicates reduced measured symptoms. Whether the improvement can be attributed to EMDR depends on the study design, including comparison groups and the timing of assessments.
4. Can someone improve without all PTSD symptoms disappearing?
Yes. Improvement may involve fewer symptoms, reduced distress, or better daily functioning. Researchers distinguish symptom reduction from no longer meeting PTSD diagnostic criteria.
5. Why do older EMDR studies use different PTSD questionnaires?
Assessment instruments have changed as PTSD diagnostic criteria have developed. Older studies may use measures based on earlier diagnostic frameworks, while newer research often uses DSM-5 or ICD-11 instruments.
Conclusion
Standardized PTSD measures play an important role in EMDR research.
Instruments such as CAPS-5, PCL-5, IES-R, and PSS help researchers assess symptom severity, examine treatment-related changes, and evaluate longer-term outcomes. Other tools, including ITQ, provide additional ways to study trauma-related symptoms.
Each instrument offers a different perspective. Some rely on clinician-administered interviews, while others capture participants' own reports.
Understanding which measures researchers used—and what those measures can establish—helps readers distinguish symptom improvement, meaningful treatment response, and changes in PTSD diagnostic status.
